CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
缺乏明确的早期临床体征和有效的筛查手段，意味着卵巢癌（OC）往往确诊时已属晚期、无法治愈。虽然常规治疗结合了最大程度的细胞减灭术和以铂类为基础的化疗，但患者常出现化疗耐药和疾病复发。免疫检查点阻断（ICB）的临床应用旨在恢复肿瘤微环境（TME）中抗肿瘤T细胞的功能。令人失望的是，尽管TIL（肿瘤浸润淋巴细胞）与OC更优的生存相关，但ICB带来的治疗获益有限。在此，我们讨论阻碍ICB充分发挥潜力的特定TME特征，尤其关注免疫、基因组和代谢改变所带来的挑战。我们探讨近期及当前旨在克服这些障碍的治疗策略，包括以免疫为基础策略的联合治疗的协同效应，并综述当前旨在最大化OC免疫治疗成功率的临床试验现状。
A lack of explicit early clinical signs and effective screening measures mean that ovarian cancer (OC) often presents as advanced, incurable disease. While conventional treatment combines maximal cytoreductive surgery and platinum-based chemotherapy, patients frequently develop chemoresistance and disease recurrence.
The clinical application of immune checkpoint blockade (ICB) aims to restore anti-cancer T-cell function in the tumour microenvironment (TME). Disappointingly, even though tumour infiltrating lymphocytes are associated with superior survival in OC, ICB has offered limited therapeutic benefits.
Herein, we discuss specific TME features that prevent ICB from reaching its full potential, focussing in particular on the challenges created by immune, genomic and metabolic alterations.
We explore both recent and current therapeutic strategies aiming to overcome these hurdles, including the synergistic effect of combination treatments with immune-based strategies and review the status quo of current clinical trials aiming to maximise the success of immunotherapy in OC.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
